Insights
Search Results
Client Highlights
8.06.26
Wilson Sonsini Advises Cylinder Health on $105 Million Acquisition by Hinge Health
On August 4, 2026, Hinge Health, a digital healthcare company, announced that it has signed a definitive agreement to acquire Cylinder Health, a leader in virtual-first digestive healthcare, for $105 million in cash consideration. Wilson Sonsini Goodrich & Rosati advised Cylinder Health on the transaction.
Alerts
7.29.26
Back-to-Back Executive Orders Shape the U.S. Quantum Agenda: What Founders and Investors Need to Know
On June 22, 2026, the administration issued two Executive Orders: Executive Order 14413, Ushering in the Next Frontier of Quantum Innovation (Quantum Innovation Executive Order) and Executive Order 14412, Securing the Nation Against Advanced Cryptographic Attacks (Post-Quantum Cryptography Executive Order). Together, the Executive Orders reinforce the federal government’s long-term commitment to quantum information science and technology (QIST) while continuing to frame quantum as both an economic and national security priority. Although they impose relatively few immediate legal obligations on most companies, the Executive Orders provide important signals about where federal investment, procurement, and strategic partnerships are likely to emerge over the coming years.
Alerts
3.13.23
Federal Circuit Affirms Jazz Pharmaceutical's Risk Evaluation and Mitigation Strategy Patent Is Not Listable in Orange Book
On February 24, 2023, the Federal Circuit held that Jazz Pharmaceuticals, Inc. (Jazz) must delist U.S. Patent No. 8,731,963 (the ’963 Patent) from the U.S. Food and Drug Administration’s (FDA’s) “Orange Book” because the claims in the ’963 Patent to a method of Risk Evaluation and Mitigation Strategies (REMS) to control access of Jazz’s Xyrem® did not qualify as “a method of using [the] drug for which approval is sought” under 21 U.S.C. § 355(b). Jazz Pharms., Inc. v. Avadel CNS Pharms., LLC, 60 F.4th 1373 (Fed. Cir. 2023).